Comparison of cytotoxicity of fluoroquinolone antimicrobial eye drops and its effect on their bioavailability

封面

如何引用文章

详细

In addition to the breadth of activity of antibacterial medications as well as to their pharmacokinetic and pharmacodynamic properties, their safety and bioavailability represent an important aspect. Currently, there is no consensus on fluoroquinolone toxicity.

The aim of the present study was to compare the total cytotoxic effect on corneal epithelium and bioavailability of three antibacterial fluoroquinolone eye drops, registered in the Russian Federation: 1) Oftaquix™ (levofloxacin 5 mg/ml; preservative benzalkonium chloride (BAC) 0.05 mg/ml; produced by Santen Oy, Finland), hereafter “levofloxacin (original)”; 2) Signicef® (levofloxacin 5 mg/ml; preservative BAC 0.1 mg/ml; produced by Sentiss Pharma Pvt. Ltd., India), hereafter “levofloxacin (generic)”; 3) Vigamox® (moxifloxacin® 5 mg/ml; preservative-free; produced by Alcon Laboratories, Inc., USA) hereafter “moxifloxacin” - using in vivo methods and determining the possible effect of preservative presence (in different concentration) or of its absence on reaching the minimal threshold concentrations of the antibiotic in the anterior chamber fluid, using the high-yield liquid chromatography combined with mass-spectrometric detection. The study showed that tested antibacterial medications could exert a cytostatic effect on the corneal epithelium at in vivo conditions and differ in their cytotoxic potential. Benzalkonium chloride presence in Signicef in a concentration twice as high than that of the main medication (Oftaquix) causes a proven by confocal microscopy effect on the corneal epithelium, and this may influence the bioavailability of the medication.

作者简介

Tamara Hintuba

North-Western State Medical University named after I.I. Mechnikov

编辑信件的主要联系方式.
Email: khintubatamara@gmail.com

ophthalmologist, research resident, Department of Ophthalmology

俄罗斯联邦, Saint Petersburg

Yuri Takhtaev

Academician I.P. Pavlov First St Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: ytakhtaev@gmail.com

MD, Prof. of the Ophthalmology department

俄罗斯联邦, Saint Petersburg

Igor Okolov

S. Fyodorov Eye Microsurgery Federal State Institution

Email: ytakhtaev@gmail.com

PhD, Head of the Clinical Bacteriological Laboratory

俄罗斯联邦, Saint Petersburg

Vera Motyleva

North-Western State Medical University named after I.I. Mechnikov

Email: ytakhtaev@gmail.com

ophthalmologist, research resident, Department of Ophthalmology

俄罗斯联邦, Saint Petersburg

Roman Shlyakman

Academician I.P. Pavlov First St Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: ytakhtaev@gmail.com

ophthalmologist, research resident, Department of Ophthalmology

俄罗斯联邦, Saint Petersburg

参考

  1. Астахов С.Ю., Вохмяков А.В. Офтальмологические фторхинолоны в лечении и профилактике глазных инфекций // Клиническая офтальмология. – 2008. – Т. 9. – № 1. – С. 28–30. [Astakhov SYu, Vokhmyakov AV. Oftal´mologicheskie ftorkhinolony v lechenii i profilaktike glaznykh infektsiy. Klinicheskaya oftal´mologiya. 2008;9(1):28-30. (In Russ.)]
  2. Астахов С.Ю., Вохмяков А.В. Эндофтальмит: профилактика, диагностика, лечение // Офтальмологические ведомости. – 2008. – Т. 1. – № 1. – С. 35–45. [Astakhov SYu, Vokhmyakov AV. Endoftal´mit: profilaktika, diagnostika, lechenie. Oftal´mologicheskie vedomosti. 2008;1(1):35-45. (In Russ.)]
  3. Вохмяков А.В., Околов И.Н., Гурченок П.А. Выбор оптимального антибиотика для профилактики инфекционных осложнений в офтальмохирургии // Клиническая офтальмология. – 2007. – Т. 8. – № 1. – С. 37–40. [Vokhmyakov AV, Okolov IN, Gurchenok PA. Vybor optimal›nogo antibiotika dlya profilaktiki infektsionnykh oslozhneniy v oftal´mokhirurgii. Klinicheskaya oftal´mologiya. 2007;8(1):37-40. (In Russ.)]
  4. Морозова Т.Е., Криворотова Н.В., Каракашев Г.В., и др. Качественное и количественное определение антибиотиков фторхинолонового ряда в содержимом передней камеры глаза методом ВЭЖХ — МС. Всероссийский симпозиум «Кинетика и динамика обменных процессов». Краснодарский край. 2012. – C. 51–52. [Morozova TE, Krivorotova NV, Karakashev GV, et al. Kachestvennoe i kolichestvennoe opredelenie antibiotikov ftorkhinolonovogo ryada v soderzhimom peredney kamery glaza metodom VEZhKh-MS. (Conference proceedings) Vserossiyskiy simpozium “Kinetika i dinamika obmennykh protsessov”. Krasnodarskiy kray. 2012. P. 51-52. (In Russ.)]
  5. Околов И.Н., Гурченок П.А., Вохмяков А.В. Нормальная микрофлора конъюнктивы у офтальмохирургических пациентов // Офтальмологические ведомости. – 2008. – Т. 1. – № 3. – С. 18–21. [Okolov IN, Gurchenok PA, Vokhmyakov AV. Normal´naya mikroflora kon´yunktivy u oftal´mokhirurgicheskikh patsientov. Oftal´mologicheskie vedomosti. 2008;1(3):18-21. (In Russ.)]
  6. Околов И.Н., Поляк М.С. Моксифлоксацин как средство профилактики и лечения инфекции глаз // Новое в офтальмологии. – 2011. – № 3. – С. 64–71. [Okolov IN, Polyak MS. Moksifloksatsin kak sredstvo profilaktiki i lecheniya infektsii glaz. Novoe v oftal´mologii. 2011;(3):64-71. (In Russ.)]
  7. Arantes T, Cavalcanti R, Diniz M, et al. Conjunctival bacterial flora and antibiotic resistance pattern in patient undergoing cataract surgery. Arq Bras Ophthalmol. 2006;69(1):33-36. doi: 10.1590/S0004-27492006000100007.
  8. Chang D, Braga-Mele R, Mamalis N, et al. Prophylaxis of postoperative endophthalmitis after cataract surgery ASCRS Cataract Clinical Committee. J Cataract Refract Surg. 2007;33(10):1801-1805. doi: 10.1016/j.jcrs.2007.07.009.
  9. ESCRS Guidelines on prevention, investigation and management of postoperative endophthalmitis. Version 2 / Editors: P. Barry, W. Behrens-Baumann, U. Pleyer, D. Seal. ESCRS. 2007. 37 p.
  10. Hehl E, Beck R, Luthard K, et al. Improved penetration of aminoglycosides and fluoroquinolones into the aqueous humour of patients by means of Acuvue contact lenses. Eur J Clin Pharmacol. 1999;55(4):317-323. doi: 10.1007/s002280050635.
  11. Koch R, Kulus S, Roessler M, et al. Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedrops. J Cataract Refract Surg. 2005;31(7):1377-1385. doi: 10.1016/j.jcrs.2004.12.063.
  12. Kovoor T, Kim A, McCulley J. Evaluation of corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens. 2004;20:90-94. doi: 10.1097/01.ICL.00000117255.97190.98
  13. Mino de Kaspar H, Kreutzer TC, Aguirre-Romo I. A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora. Am J Ophthalmol. 2008;145(1):136-142. doi: 10.1016/j.ajo.2007.08.031.
  14. Sandvig KU, Dannevig L. Postoperative endophthalmitis: Establishment and results of a national registry. J Cataract Refract Surg. 2003;29(7):1273-1280. doi: 10.1016/S0886-3350(02)02048-5.
  15. Tan C, Wong H, Yang F. Epidemiology of postoperative endophthalmitis in an Asian population: 11-year incidence and effect of intracameral antibiotic agents. J Cataract Refract Surg. 2012;38(3):425-30. doi: 10.1016/j.jcrs.2011.09.040.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Hintuba T.S., Takhtaev Y.V., Okolov I.N., Motyleva V.A., Shlyakman R.B., 2017

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
 


##common.cookie##